CSL Limited Reports Revenue Decline Amid 'Reset Year,' Lays Out Restructuring Plan
The Australian biotech giant posted a 1% revenue decline to $15.8 billion as interim CEO Gordon Naylor outlines stabilization efforts and acknowledges significant headwinds in iron and dialysis portfolios.
Revenue and Profitability Decline
CSL Limited reported fiscal 2026 revenue of $15.8 billion, down 1% on a constant currency basis, as the Australian biopharmaceutical company navigates what interim CEO Gordon Naylor characterized as "a reset year" (earnings call, 2026-08-18). Underlying net profit after tax fell 3% to $2.8 billion.
The company's three business segments posted mixed results. CSL Behring, the company's largest division, saw revenue decline 1% to $11.4 billion. CSL Vifor grew 3% to $2.4 billion, while CSL Seqirus fell 8% to $2 billion.
Naylor, who assumed the interim CEO role earlier this year, acknowledged that "financial performance had fallen short of expectations" but emphasized that "the industry structures in which we compete remain robust" (earnings call, 2026-08-18).
Immunoglobulin Stabilizes After Inventory Normalization
CSL Behring's immunoglobulin revenue remained flat for the full year, impacted by what the company described as normalization of U.S. channel inventory. However, second-half performance showed improvement, with Ig revenue increasing 7% compared to the prior comparable period and 4% sequentially.
"We regard this as an early indicator that the commercial investments we've made in the U.S. are yielding benefits," Naylor said (earnings call, 2026-08-18).
Albumin revenue declined 17%, primarily due to cost containment measures in China that reduced market value. The company noted "a slowing in the rate of decline," with second-half revenue down just 5% year-over-year.
The newer product ANDEMBRY "exceeded our initial launch expectations" and is now available in 19 markets, while HEMGENIX grew 25% (earnings call, 2026-08-18).
Significant Headwinds at CSL Vifor
CSL Vifor faces substantial structural challenges that Naylor described in detail. The iron portfolio declined 16% as generic competition intensified in both the U.S. and Europe. Injectafer now competes against generic entrants in the United States, while the European iron portfolio continues to experience "substantial price erosion" (earnings call, 2026-08-18).
Velphoro, which benefited from inclusion in the U.S. TDAPA reimbursement arrangement, will lose that advantage on December 31, 2026. The company expects sales will "decline substantially from their recent highs" (earnings call, 2026-08-18).
Additionally, the European Commission revoked the marketing authorization for Tavneos in Europe, though the company expressed respect for "the outcome of the regulatory process" (earnings call, 2026-08-18).
To mitigate these headwinds, CSL has integrated the commercial and medical organizations of CSL Behring and CSL Vifor, enabling combined management structures and resource deployment across the portfolio.
Seqirus Gains Market Share
CSL Seqirus delivered what Naylor called solid performance despite an 8% revenue decline driven by the nonrecurrence of pre-pandemic avian influenza sales. Seasonal influenza revenue grew 4%, with Seqirus being "the only global vaccine company to grow seasonal influenza revenue year-on-year" (earnings call, 2026-08-18).
Capital Returns and Transformation
The company completed a share buyback of approximately AUD 1 billion and maintained its dividend in U.S. dollar terms. The transformation program delivered $176 million in savings during FY26, ahead of target. Cash flow from operations remained strong at $3.5 billion.
Naylor, who is not a candidate for the permanent CEO role, said the board search is "progressing to plan" with an "impressed" board reviewing a shortlist of candidates (earnings call, 2026-08-18).
This article was generated by MarginX from the earnings call on 2026-08-18. It is not investment advice.